The combination of LXR agonist GW3965 and carboplatin reduces the proliferation of basal‐like breast cancer patient‐derived xenografts through reduced activity of targets of E2F transcription factors, reduced heregulin protein expression, and increased activity of cholesterol homeostasis. This evidence concerns the gene NRG1 and breast cancer.